@LegendUSMA Legend Biotech Medical Affairs

Legend Biotech Medical Affairs posts on X about link, events, in the, cart the most. They currently have [---] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

• [--] Week [---] -74%
• [--] Month [-----] +258%
• [--] Months [-----] -8.20%

Mentions: [--] #

• [--] Week [--] -30%
• [--] Month [--] +9.10%
• [--] Months [--] +67%

Followers: [---] #

• [--] Week [---] +0.87%
• [--] Month [---] +3.60%
• [--] Months [---] +100%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 38.3%

Social topic influence link 27.66%, events 8.51%, in the 6.38%, cart 6.38%, science 4.26%, longterm 4.26%, hope 2.13%, salt 2.13%, center 2.13%, momentum 2.13%

Top accounts mentioned or mentioned by @surbhisidanamd @bhemato @comycongress @yilinmdphd @endmyeloma @moffittnews @plasmacellpete @leshune @amokhanmd @sandsjacob @tombmt133 @cohenadmmdoc @noopurrajemd @abhinavdeol @berdejajesus @lesokhinmd @dradrianarossi @szusmani @adamjschoenfeld @janakirammurali

Top assets mentioned Frontline Ltd. (FRO)

Top Social Posts

Top posts by engagements in the last [--] hours

"Excited for the #TANDEM26 Annual Meeting and the chance to advance patient-centered innovation together. We hope you will connect with our Medical Affairs team at Booth #301 for those attending live in Salt Lake City. For more on our science: #mmsm #CART https://bit.ly/4sZ9Wvy https://bit.ly/4sZ9Wvy"
X Link 2026-02-03T19:56Z [---] followers, [---] engagements

"See Dr. Luciano Costa (@End_myeloma) at #TANDEM26 present long-term progression-free survival outcomes with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma in the CARTITUDE-4 study. For more link here: #mmsm https://bit.ly/3LY4fx6 https://bit.ly/3LY4fx6"
X Link 2026-02-05T15:31Z [---] followers, [---] engagements

"Dr. Binod Dhakal (@bhemato) presents at #TANDEM26 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase [--] CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. For more link here: #mmsm #CART https://bit.ly/4pSeNMc https://bit.ly/4pSeNMc"
X Link 2026-02-05T17:15Z [---] followers, [---] engagements

"Dr. Doris Hansen from @MoffittNews presents at #TANDEM26 on bridging therapy response and pre-lymphodepletion plasma cell burden as determinants of BCMA-directed safety and efficacy outcomes in relapsed/refractory multiple myeloma. Link: #mmsm. https://bit.ly/3LOuExk https://bit.ly/3LOuExk"
X Link 2026-02-05T20:12Z [---] followers, [---] engagements

"Dr. Surbhi Sidana (@SurbhiSidanaMD) presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in len-refractory multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/49AV3HZ https://bit.ly/49AV3HZ"
X Link 2026-02-05T20:56Z [---] followers, [---] engagements

"At #TANDEM26 Dr. Doris Hansen of @MoffittNews presents characterization and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm. https://bit.ly/4qH1I9G https://bit.ly/4qH1I9G"
X Link 2026-02-05T21:18Z [---] followers, [---] engagements

"Robert Bowden (Johnson & Johnson) presents at #TANDEM26 on improved manufacturing outcomes with out-of-specification BCMA-directed #CART therapy in earlier lines of therapy. For more link here: #mmsm https://bit.ly/3NxfNI9 https://bit.ly/3NxfNI9"
X Link 2026-02-06T00:25Z [---] followers, [---] engagements

"At the [----] ASH Annual Meeting our focus remains clear: driving innovation that puts patients at the center. Excited to collaborate and share progress with the hematology community For more link here: #mmsm #lymsm https://bit.ly/4ps38UB https://bit.ly/4ps38UB"
X Link 2025-12-04T15:20Z [---] followers, [---] engagements

"Thank you to those who joined us during #Tandem26 and engaged with our data. Your continued partnership advances the science of cellular therapy and supports progress in care for patients with multiple myeloma. Looking forward to continuing the momentum at #ASCO26. #mmsm #CART"
X Link 2026-02-07T17:09Z [---] followers, [---] engagements

"See our Community Guidelines"
X Link 2025-05-12T15:49Z [--] followers, [---] engagements

"Welcome to @LegendUSMA We are dedicated to sharing updates on the research and clinical development of innovative cellular therapies to improve the lives of patients. We hope you will follow us and look forward to the scientific exchange. See our community guidelines. #CellRx"
X Link 2025-05-14T16:30Z [--] followers, [---] engagements

"For US HCPs see an e-poster at @COMyCongress on MRD negativity outcomes in the Phase [--] CARTITUDE-4 trial of a BCMA-directed CAR-T cell therapy vs standard of care in patients with Len-refractory multiple myeloma after 1-3 prior lines of therapy: #mmsm https://bit.ly/4kgHqQD https://bit.ly/4kgHqQD"
X Link 2025-05-16T14:53Z [--] followers, [---] engagements

"For US HCPs see an e-poster at @COMyCongress of infections and immune reconstitution in the Phase [--] CARTITUDE-4 trial of a BCMA-directed CAR-T cell therapy vs standard of care in patients with Len-refractory multiple myeloma after 1-3 prior lines: #mmsm https://bit.ly/4dBqh2h https://bit.ly/4dBqh2h"
X Link 2025-05-16T17:49Z [--] followers, [---] engagements

"For US HCPs see a @COMyCongress presentation showing effectiveness of bridging therapy corresponds to improved outcomes after BCMA-directed CAR-T therapy in the Phase [--] CARTITUDE-4 trial of patients with relapsed Len-refractory multiple myeloma: #mmsm https://bit.ly/4keA4Nv https://bit.ly/4keA4Nv"
X Link 2025-05-17T21:00Z [--] followers, [---] engagements

"For US HCPs see a @COMyCongress encore presentation of overall survival outcomes with a BCMA-directed CAR-T therapy vs standard of care in the Phase [--] CARTITUDE-4 trial for relapsed Len-refractory multiple myeloma: #mmsm https://bit.ly/4keA4Nv https://bit.ly/4keA4Nv"
X Link 2025-05-18T00:00Z [--] followers, [---] engagements

"Now published for US HCPs: results of a matching-adjusted indirect comparison of a BCMA-directed CAR-T cell therapy vs standard of care therapies for patients with relapsed/refractory multiple myeloma. Read more: #mmsm @SurbhiSidanaMD @leshune @AMoKhanMD https://bit.ly/4jY248w https://bit.ly/4jY248w"
X Link 2025-05-19T15:35Z [--] followers, [---] engagements

"We are excited to be in Chicago for #ASCO25 Come by our Medical Booth (#11113) to meet our medical team and learn more about the research were presenting at this years meeting. See the ASCO hub for our abstracts. #mmsm #lcsm #GastricCancer #Pancsm #CellRx"
X Link 2025-05-29T14:07Z [--] followers, [---] engagements

"For US HCPs at #ASCO25 Dr. David Zhen presents preliminary results of a Phase [--] study of an autologous Claudin 18.2-targeted CAR-T therapy in patients with advanced gastroesophageal adenocarcinoma. For more: #GastricCancer #EsophagealCancer #Pancsm http://bit.ly/43d8DOx http://bit.ly/43d8DOx"
X Link 2025-05-30T18:33Z [--] followers, [---] engagements

"For US HCPs at #ASCO25 Dr. Jacob Sands (@sands_jacob) presents results of a Phase [--] study of an armored DLL3-targeted CAR-T therapy in patients with relapsed small cell lung cancer and large cell neuroendocrine carcinoma. For more: #sclc #lcnec #lcsm https://bit.ly/4d06n0e https://bit.ly/4d06n0e"
X Link 2025-05-31T11:28Z [--] followers, [---] engagements

"For US HCPs at #ASCO25 Dr. Surbhi Sidana (@SurbhiSidanaMD) presents survival outcomes of subgroups in the CARTITUDE-4 study after treatment with a BCMA-directed CAR-T cell product for early line relapsed/refractory multiple myeloma. For more: #mmsm http://bit.ly/4d3YYwX http://bit.ly/4d3YYwX"
X Link 2025-06-01T12:38Z [--] followers, [----] engagements

"For US HCPs at #ASCO25 Dr. Peter Voorhees (@PlasmaCellPete) presents long-term follow-up of the CARTITUDE-1 study with [--] years of follow-up after treatment with a BCMA-directed CAR-T cell product for relapsed/refractory multiple myeloma. For more: #mmsm http://bit.ly/3GVbyTd http://bit.ly/3GVbyTd"
X Link 2025-06-03T12:51Z [--] followers, [---] engagements

"NOW PUBLISHED for US HCPs: Long-term remission and survival after treatment with a BCMA-directed CAR-T cell therapy in CARTITUDE-1 for patients with relapsed/refractory multiple myeloma. Read more: #mmsm https://bit.ly/4dG13zu https://bit.ly/4dG13zu"
X Link 2025-06-03T13:08Z [--] followers, [---] engagements

"Authors: Sundar Jagannath @TomBmt133 @YiLinMDPhD @CohenAd_MMdoc @NoopurRajeMD Myo Htut @abhinav_deol Mounzer Agha @BerdejaJesus @LesokhinMd Jessica Liegel @Dr_AdrianaRossi Alex Lieberman-Cribbin @szusmani @bhemato Samir Parekh Andrzej Jakubowiak @PlasmaCellPete"
X Link 2025-06-03T13:08Z [--] followers, [----] engagements

"For US HCPs at #EHA25 see Dr. Sundar Jagannath (Mount Sinai) present long-term follow-up of the CARTITUDE-1 study with [--] years of follow-up after treatment with a BCMA-directed CAR-T cell product for relapsed/refractory multiple myeloma. #mmsm https://bit.ly/4jvExLi https://bit.ly/4jvExLi"
X Link 2025-06-12T14:54Z [--] followers, [---] engagements

"For US HCPs at #EHA25 see Dr. Yi Lin (@YiLinMDPhD) present an analysis of absolute lymphocyte count (ALC) as a key biomarker for monitoring safety after a BCMA-directed CAR-T cell therapy: #mmsm https://bit.ly/3Fodofe https://bit.ly/3Fodofe"
X Link 2025-06-14T13:00Z [--] followers, [---] engagements

"For US HCPs at #EHA25 Dr. Yael Cohen presents survival outcomes of subgroups in the CARTITUDE-4 study after treatment with a BCMA-directed CAR-T cell product for early line relapsed/refractory multiple myeloma. For more: #mmsm http://bit.ly/4kdkMcx http://bit.ly/4kdkMcx"
X Link 2025-06-14T15:00Z [--] followers, [---] engagements

"News from the US Food and Drug Administration (FDA): The Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been eliminated. A thread 🧵"
X Link 2025-06-30T19:00Z [--] followers, [--] engagements

"For US HCPs at #SOHO2025 Yi Lin (@YiLinMDPhD) of Mayo Clinic Rochester presents an encore presentation analyzing ALC as a key biomarker for safety monitoring after a BCMA-directed #CART cell therapy. #mmsm"
X Link 2025-09-03T13:28Z [--] followers, [---] engagements

"For US #HCPs at #SOHO2025 Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents an encore presentation analyzing survival outcomes of various subgroups in CARTITUDE-4 of a BCMA-directed #CART therapy versus standard of care. #mmsm"
X Link 2025-09-03T16:49Z [--] followers, [---] engagements

"For US HCPs at #WCLC25 see Dr. Adam J. Schoenfeld (@AdamJSchoenfeld) present results from a phase [--] study of a DLL3-targeted #CART cell therapy in small cell lung and large cell neuroendocrine cancers. See more: #lcsm #sclc #lcnec http://bit.ly/4g2po3W http://bit.ly/4g2po3W"
X Link 2025-09-09T10:00Z [--] followers, [--] engagements

"For US HCPs at #IMS25 Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/4pfEirI https://bit.ly/4pfEirI"
X Link 2025-09-17T13:45Z [--] followers, [---] engagements

"For US HCPs at #IMS25 see Dr. Yael Cohen present updated results from CARTITUDE-2 Cohort D of a BCMA-directed #CART therapy +/- lenalidomide maintenance for multiple myeloma patients with a suboptimal response to frontline ASCT. Abstracts here: #mmsm https://bit.ly/3VG16Dg https://bit.ly/3VG16Dg"
X Link 2025-09-19T17:09Z [--] followers, [--] engagements

"For US HCPs at #IMS25 Yi Lin (@YiLinMDPhD) of Mayo Clinic Rochester presents an encore presentation analyzing ALC as a key biomarker for safety monitoring after a BCMA-directed #CART cell therapy. For IMS abstracts link here: #mmsm http://bit.ly/45VN5Yf http://bit.ly/45VN5Yf"
X Link 2025-09-17T12:59Z [---] followers, [---] engagements

"For US HCPs at #IMS25 Dr. Murali Janakiram (@JanakiramMurali) from City of Hope presents a descriptive analysis of healthcare resource utilization following inpatient or outpatient infusion of a BCMA-directed #CART therapy. Abstracts here: #mmsm https://bit.ly/3IaTAx8 https://bit.ly/3IaTAx8"
X Link 2025-09-19T13:08Z [--] followers, [---] engagements

"Join Dr. Luciano Costa (@End_myeloma) for an oral presentation at #ASH25 to learn about the long-term progression-free survival benefit with a BCMA-directed #CART therapy in standard-risk relapsed / refractory multiple myeloma. For more link here: #mmsm https://bit.ly/3LOC6bn https://bit.ly/3LOC6bn"
X Link 2025-12-06T13:44Z [---] followers, [----] engagements

"Dr. Jingwei Yu (Tianjin Medical University Cancer Institute) presents a phase [--] study of a novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell NHL. Link: #lymsm #CART https://bit.ly/4ocJE5j https://bit.ly/4ocJE5j"
X Link 2025-12-06T15:34Z [---] followers, [---] engagements

"Dr. Binod Dhakal (@bhemato) presents at #ASH25 on effectiveness of bridging therapy corresponds to improved outcomes in the Phase [--] CARTITUDE-4 study of patients with relapsed lenalidomide-refractory multiple myeloma. For more link here: #mmsm #CART https://bit.ly/4oRFzo9 https://bit.ly/4oRFzo9"
X Link 2025-12-06T18:20Z [---] followers, [---] engagements

"Robert Bowden (Johnson & Johnson) presents at #ASH25 on improved manufacturing outcomes with BCMA-directed #CART therapy in earlier lines of therapy. For more link here: #mmsm https://bit.ly/3KeuC0Q https://bit.ly/3KeuC0Q"
X Link 2025-12-06T19:01Z [---] followers, [---] engagements

"Dr. Doris Hansen presents at #ASH25 on bridging therapy response and low pre-lymphodepletion plasma cell burden associations with improved safety and efficacy outcomes of a BCMA-directed #CART therapy in multiple myeloma. Link: #mmsm. https://bit.ly/4p32Rr6 https://bit.ly/4p32Rr6"
X Link 2025-12-06T20:24Z [---] followers, [---] engagements

"At #ASH25 Dr. Doris Hansen presents real-world incidence and management of non-ICANS neurological events following a BCMA-directed #CART cell therapy in multiple myeloma. Link: #mmsm. https://bit.ly/3KfHNi7 https://bit.ly/3KfHNi7"
X Link 2025-12-07T15:54Z [---] followers, [---] engagements

"Dr. Christopher Strouse (@strouse_chris) presents comparative efficacy of a BCMA-directed #CART cell therapy vs a BCMA-directed ADC-based triplet in patients with relapsed/refractory multiple myeloma after [--] prior therapies using an MAIC. Link: #mmsm. https://bit.ly/48qdYVh https://bit.ly/48qdYVh"
X Link 2025-12-07T17:09Z [---] followers, [---] engagements

"Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford University presents a quality-adjusted survival analysis of neurological events with a BCMA-directed #CART therapy vs standard of care in multiple myeloma patients in the CARTITUDE-4 trial. Link: #mmsm. https://bit.ly/48fwXRi https://bit.ly/48fwXRi"
X Link 2025-12-08T13:25Z [---] followers, [---] engagements

"A heartfelt thank you to all who joined us at #ASH25 attended sessions and visited our posters. Together were pushing boundaries in #CART therapy and accelerating better outcomes for patients with #mmsm and #lymsm"
X Link 2025-12-09T21:03Z [---] followers, [---] engagements

"ICYMI: we recently celebrated the opening of our new [-----] square foot state-of-the-art cell therapy research facility in downtown Philadelphia that will help support Legends pipeline of next-generation cell therapies. For more about Legends pipeline: https://bit.ly/3XJDsqu https://bit.ly/3XJDsqu"
X Link 2025-12-17T15:53Z [---] followers, [---] engagements

"NEW in Lancet Oncology: Latest findings from CARTITUDE-4 study report on survival outcomes in patients with relapsed/refractory multiple myeloma treated with a BCMA #CART therapy as early as first relapse compared with standard of care. #mmsm Read more: https://bit.ly/4qJUkKp https://bit.ly/4qJUkKp"
X Link 2026-01-08T17:43Z [---] followers, [---] engagements

"US-based authors: Dr. Binod Dhakal (@bhemato) of MCW and Dr. Surbhi Sidana (@SurbhiSidanaMD) of Stanford"
X Link 2026-01-08T17:43Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing